Skip to main content
Premium Trial:

Request an Annual Quote

DxNA Licenses Staph Assay from PathoGene for Use on GeneStat System

Premium

DxNA has acquired exclusive rights to run PathoGene's multiplexed Staphylococcus MRSA+ assay on DxNA's real-time PCR-based GeneStat platform, the companies said this week.

Specifically, St. George, Utah-based DxNA will combine PathoGene's assay with its own master mix chemistry in a cartridge format for use on the GeneStat system, DxNA CEO David Taus told PCR Insider.

PathoGene's Staphylococcus MRSA+ assay simultaneously identifies and differentiates three of the most common pathogens of hospital-acquired, surgical site, medical device, and skin and soft tissue infections, in about an hour. The companies noted that the test is different from current commercially available assays for methicillin-resistant S. aureus because it includes multi-drug-resistant coagulase-negative Staphylococcus strains, which are much more common infections than MRSA.

Meantime, DxNA's GeneStat platform is a cartridge-based system for performing DNA- and/or RNA-based multiplexed real-time PCR assays to detect infectious disease agents in humans and animals, and to detect biological contaminants in the environment. The company said that the system accepts a number of sample types and can be run with minimal training in either laboratory or field settings.

"PathoGene's novel approach with this Staph assay provides rapid clinical answers … making [it] an ideal complement to our GeneStat platform," Taus said in a statement.

In 2009, DxNA's GeneStat 2009 H1N1 influenza virus was granted emergency use authorization by the US Food and Drug Administration (PCR Insider, 12/17/2009).

PathoGene, based in Flagstaff, Ariz., is a 2008 spinout of the Translational Genomics Institute and Northern Arizona University. The company was founded to develop PCR-based assays for difficult-to-treat and drug-resistant infectious diseases (PCR Insider, 8/19/2010).

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.